Repositorio Dspace

Validation and Exploratory Refinement of the HFA-ICOS Score for Cardiovascular Risk in Proteasome Inhibitor-Treated Multiple Myeloma: Single-Center Retrospective Study

Mostrar el registro sencillo del ítem

dc.contributor.author Pons-Fuster, Eduardo
dc.contributor.author Riquelme-Pérez, Alejandro
dc.contributor.author Shumbar, Vyacheslav
dc.contributor.author González-Ponce, Celia-María
dc.contributor.author Fernández-Ávila, Juan-José
dc.contributor.author Ramon-Martínez, Andrés
dc.contributor.author Moreno-Belmonte, María-José
dc.contributor.author Cabañas-Perianes, Valentín
dc.contributor.author Pascual-Figal, Domingo-Andrés
dc.contributor.author Díaz-Carrasco, María-Sacramento
dc.contributor.author Caro-Martínez, César
dc.date.accessioned 2026-09-17T12:15:38Z
dc.date.available 2026-09-17T12:15:38Z
dc.date.issued 2026-06-12
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/28138
dc.description.abstract Background: Proteasome inhibitors (PIs) are integral in multiple myeloma (MM) treatment but carry a substantial risk of cardiovascular adverse events (CVAEs). The Heart Failure Association-International Cardio-Oncology Society (HFA-ICOS) risk score was designed to identify patients at risk of cardiotoxicity, but its performance in MM remains uncertain. Methods: We retrospectively evaluated 98 patients with MM or primary amyloidosis treated with PIs between 2019 and 2024 to externally validate and refine this score. Results: CVAEs occurred in 22 patients (22.5%), predominantly heart failure. The original HFA-ICOS model demonstrated modest predictive accuracy (AUC 0.66) and sensitivity (50%), with frequent risk overclassification. Carfilzomib exposure (HR 4.68, 95% CI 1.47-14.90; p = 0.009) and elevated NT-proBNP before cycle 2 (>300 pg/mL; HR 3.13, 95% CI 1.10-8.93; p = 0.033) independently predicted CVAEs. A dynamic model incorporating these parameters and adjusting the age threshold to ?65 years was associated with improved discrimination (AUC 0.72, p = 0.032), model fit (?AIC = -4), and CVAE-free survival stratification (p = 0.026), achieving 90.9% sensitivity. Conclusions: These findings indicate that the original HFA-ICOS score has limited prognostic value in PI-treated MM patients. Incorporating early NT-proBNP monitoring, carfilzomib exposure, and refined age categorization may improve risk prediction and support more personalized cardiovascular surveillance strategies in cardio-oncology. However, this refined dynamic model should be regarded as exploratory and requires validation in larger independent cohorts before it can be considered for clinical application.
dc.language.iso eng
dc.publisher MDPI
dc.rights Atribución/Reconocimiento 4.0 Internaciona
dc.rights.uri https://creativecommons.org/licenses/by/4.0/deed.es *
dc.title Validation and Exploratory Refinement of the HFA-ICOS Score for Cardiovascular Risk in Proteasome Inhibitor-Treated Multiple Myeloma: Single-Center Retrospective Study
dc.type info:eu-repo/semantics/article 
dc.identifier.pmid 42352458
dc.relation.publisherversion https://www.mdpi.com/2072-6694/18/12/1924
dc.type.version info:eu-repo/semantics/publishedVersion 
dc.identifier.doi 10.3390/cancers18121924
dc.journal.title CANCERS
dc.identifier.essn 2072-6694


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento 4.0 Internaciona Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento 4.0 Internaciona

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta